Prime Medicine (PRME) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Prime Medicine (NASDAQ: PRME):

• 10/3/2026 – Prime Medicine was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/28/2026 – Prime Medicine had its “market outperform” rating reaffirmed by Jefferies Financial Group Inc..
• 9/25/2026 – Prime Medicine had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/25/2026 – Prime Medicine had its “buy” rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
• 9/12/2026 – Prime Medicine was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/31/2026 – Prime Medicine had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/25/2026 – Prime Medicine is now covered by Chardan Capital. They set a “buy” rating and a $7.00 price target on the stock.
• 8/25/2026 – Prime Medicine is now covered by Chardan Capital. They set a “buy” rating and a $7.00 price target on the stock.
• 8/18/2026 – Prime Medicine is now covered by BMO Capital Markets. They set an “outperform” rating and a $9.00 price target on the stock.
• 8/18/2026 – Prime Medicine is now covered by BMO Capital Markets. They set an “outperform” rating and a $9.00 price target on the stock.

Prime Medicine, Inc (NASDAQ:PRME) is a biotechnology company developing genetic medicines based on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company’s platform is intended to address a broad range of genetic diseases while potentially reducing some of the limitations associated with earlier gene-editing approaches.

Prime Medicine is advancing an investigational pipeline of therapies for diseases caused by genetic mutations.